Online inquiry

IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6846MR)

This product GTTS-WQ6846MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL3RA gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3563
UniProt ID P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6846MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10438MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ103MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ9622MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ8871MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ13132MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ5900MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ14057MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ8103MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW